Sinonasal Plasmablastic Lymphoma Arising in the Setting of Recurrent Nasal Polyposis in an Immunocompetent Individual

1. Castillo, JJ, Winer, ES, Stachurski, D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-2053.
Google Scholar | Crossref | Medline2. Castillo, JJ, Reagan, JL. Plasmablastic lymphoma: a systematic review. Sci World J. 2011;11:687-696.
Google Scholar | Crossref3. Morscio, J, Dierickx, D, Nijs, J, Verhoef, G, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients. Am J Surg Pathol. 2014;38(7):875-886.
Google Scholar | Crossref | Medline4. Castillo, JJ, Bibas, M, Miranda, RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-2330.
Google Scholar | Crossref | Medline5. Castillo, JJ, Winer, ES, Stachurski, D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuke. 2011;11(2):185-189.
Google Scholar | Crossref6. Delecluse, HJ, Anagnostopoulos, I, Dallenbach, F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413-1420.
Google Scholar | Crossref | Medline7. Belli, S, Yildirim, M, Eroglu, S, Emre, FK. Single-sided sinonasal mass: a retrospective study. North Clin Istanbul. 2018;5(2):139-143.
Google Scholar | Medline8. Wynn, R, Har-El, G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813.
Google Scholar | Crossref | Medline9. Nhlonzi, G, Mwazha, A, Naicker, N. Plasmablastic neoplasms with unusual histomorphology: a report of two cases. Hum Pathol Case Report. 2020;22(200441):2214-3300.
Google Scholar10. Shannon-Lowe, C, Rickinson, AB, Bell, AI. Epstein-Barr virus-associated lymphomas. Phil Trans Biol Sci. 2017;372(1732):20160271.
Google Scholar | Crossref | Medline11. Makady, NF, Ramzy, D, Ghaly, R, Abdel-Malek, RR, Shohdy, KS. The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes. Clin Lymphoma Myeloma Leuke. 2021;21(3):e255-e263.
Google Scholar | Crossref12. Rudresha, AH, Lakshmaiah, KC, Agarwal, A, et al. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India. South Asia J Cancer. 2017;6(2):69-71.
Google Scholar | Crossref | Medline13. Witte, HM, Künstner, A, Hertel, N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2021. [published online ahead of print, 2021 Oct 29]. doi:10.1182/bloodadvances.2021005486.
Google Scholar | Crossref14. Ramis-Zaldivar, JE, Gonzalez-Farre, B, Nicolae, A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682-2693.
Google Scholar | Crossref | Medline15. Frontzek, F, Staiger, AM, Zapukhlyak, M, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12(1):5183.
Google Scholar | Crossref | Medline16. Shaim, H, Estrov, Z, Harris, D, et al. The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide. Front Immunol. 2018;8:1773.
Google Scholar | Crossref | Medline17. Makady, NF, Ramzy, D, Ghaly, R, Abdel-Malek, RR, Shohdy, KS. The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes. Clin Lymphoma, Myeloma & Leukemia. 2021;21(3):e255-e263. doi:10.1016/j.clml.2020.11.025.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif